Copyright © 2021 MarketWatch, Inc. All rights reserved. Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. Creating Possible | The way we see it, the impossible is not impossible. Gilead Sciences, Inc. (Nasdaq:GILD), in collaboration with GlaxoSmithKline (GSK), today announced plans for an international, event-driven (morbidity and mortality) clinical trial to study combination therapy versus monotherapy in a first-line treatment setting for pulmonary arterial hypertension (PAH). Oct 28, 2020 at 4:30 PM EDT Third Quarter 2020 Gilead Sciences Earnings Conference Call. Finanztrends.info zeigt ihnen, was in der Welt der Aktien los ist und berichtet live von den bedeutendsten Plätzen des deutschsprachigen Finanzmarkts. Dec 2, 2020 at 11:20 AM EST Gilead Sciences at the 3rd Annual Evercore ISI HealthCONx Conference. Für die aufgeführten Inhalte kann keine Gewährleistung für die Vollständigkeit, Richtigkeit und Genauigkeit übernommen werden. Privacy Notice, and
Klik her for at følge aktiekursen i realtid Standard review takes about 10 months, while priority review … Fauci says it could be a ‘game changer’ if Trump urged loyalists to get vaccinated, Duke University puts entire undergraduate population into quarantine, California’s Newsom admits pandemic mistakes but says gubernatorial recall push is not justified, Idaho ends Powerball participation amid lawmaker concern that Australia could use lottery revenue for anti-gun measures, ‘No peace’ for markets until 10-year Treasury yield hits 2%, strategist says, Wisconsin Republican Ron Johnson’s remark about feeling safe in Senate during Capitol riot labeled racist, Marco Rubio links his support for unionizing Amazon workers with an accusation of ‘wokeness’ at company, Vaccine-site volunteers frequently rewarded with early shots, What Bond Investors Should Watch This Week: Fed Decision Edition, Gilead Sciences Inc. stock falls Friday, underperforms market, Gilead Sciences Inc. stock underperforms Thursday when compared to competitors, Roche late trial of COVID-19 treatment disappoints, Gilead Sciences Inc. stock underperforms Wednesday when compared to competitors, Gilead Sciences Inc. stock underperforms Tuesday when compared to competitors, Gilead Sciences Inc. stock underperforms Monday when compared to competitors despite daily gains, IPO for Oxford COVID-19 vaccine startup in peril, Gilead Sciences Inc. stock outperforms market on strong trading day, Gilead Sciences Inc. stock rises Thursday, outperforms market, NIH to study three experimental COVID-19 treatments, U.S. COVID death toll above 518,000 as Biden adds voice to outrage at Texas and Mississippi for reopening, NIH tells Vir that experimental COVID-19 therapy may not benefit patients, Gilead Sciences Inc. stock outperforms market despite losses on the day. Aktuelle News zum Thema Gilead Sciences im Überblick Hier finden Sie ausführliche Nachrichten und Analysen der FAZ. Gilead Sciences, Inc. Common Stock (GILD) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig. (GILD) investigational, long-acting HIV-1 capsid inhibitor, lenacapavir, met primary endpoint in Phase 2/3 Study in heavily treatment-experienced Intraday data delayed at least 15 minutes or per exchange requirements. BACK TO MAIN MENU Company Statements Gilead Announces Plans for New Location in North Carolina’s Research Triangle Region Dedicated to Business Services Gilead Sciences Statement on the Passing of the Honorable George P. Shultz, PhD Gilead Sciences Statement on Recent Events in Washington, D.C. Gilead Announces New Arm of HIV Women’s Prevention Study to Evaluate the … Gilead Sciences Inc. stock rises Tuesday, outperforms market, Gilead Sciences Inc. stock rises Monday, still underperforms market, Gilead Sciences Inc. stock falls Thursday, still outperforms market, Positive news on COVID vaccines weighs against concerns over new variants, GSK to refocus study of experimental COVID-19 antibody treatment on patients 70 and older, Roche (RHHBY) & Gilead's Drug Combo Study for COVID-19 Fails, Gilead Sciences (GILD) Received its Third Buy in a Row, 3 Deep Value Stocks for Income and High Total Returns, Biotech Stock Roundup: AMGN's Acquisition, ACAD's Regulatory Update & More, Gilead Sciences (GILD) Gains As Market Dips: What You Should Know, Gilead's (GILD) CAR T Cell Therapy Yescarta Gets FDA Nod for FL, Merck's (MRK) COVID-19 Drug Shows Promise in Mid-Stage Study, Gilead’s Kite Receives FDA Approval For Yescarta Immunotherapy; Street Sees 17% Upside. For the best MarketWatch.com experience, please update to a modern browser. Gilead buys more Arcus Biosciences stock, at a price above the record close Arcus Biosciences Inc. disclosed Monday that Gilead Sciences Inc. boosted its stake in the oncology-focused biopharmaceutical company, through the purchase of $220.35 million worth of stock. Gilead Sciences Inc. Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. Gilead Sciences and Wake Forest University School of Divinity Partner to Address HIV Epidemic Through Faith-Based Programming and Community Outreach February 10, 2021 Kite Announces New ZUMA-1 Cohort Analysis Evaluating Prophylactic Corticosteroid Use With Yescarta® in Patients With Relapsed or Refractory Large B-cell lymphoma February 10, 2021 I can't squeeze Nong Daek Khao acne. ADRs). The study, AMBITION (a randomized, double-blind, multicenter study of first-line … © 1999-2021 finanzen.net GmbH, DAX geht mit Abschlägen ins Wochenende -- US-Börsen letztlich uneinheitlich -- VW meldet Absatzboom -- Renault stößt Daimler-Anteil ab -- T-Mobile, Deutsche Bank, Fortum, BMW im Fokus, Das waren die größten Finanzskandale im Jahr 2020, Den Rubel rollen lassen: Warum die Devise wieder steigen dürfte, Kostenfrei registrieren und Vorteile nutzen, VW einigt sich mit Betriebsrat auf weitere Schritte zum Stellenabbau, Bitcoin, Ethereum, Litecoin & Co.: Wie sich die Kryptokurse heute entwickeln, Taiwan Semiconductor Manufacturing Co. Ltd. (TSMC) (Spons. Gilead Sciences at the 39th Annual J.P. Morgan Healthcare Conference. Gilead’s Covid-19 Antiviral Has Been a Major Earner. There are currently no items in this Watchlist. Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. Something went wrong while loading Watchlist. GILEAD SCIENCES Aktienanalyse: Wie sicher ist die Aktie? Have Watchlists? The firms primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. ISIN-fondskode US3755581036. GILEAD SCIENCES Schätzungen: Hier finden Sie einen Überblick über die erwartete Entwicklung der wichtigsten Kennzahlen von GILEAD SCIENCES … Aktien » Nachrichten » GILEAD SCIENCES AKTIE » Galapagos, Gilead Discontinue Late-stage Trials In Idiopathic Pulmonary Fibrosis Push Mitteilungen FN als Startseite GILEAD SCIENCES INC Aktuelle Empfehlungen zur GILEAD SCIENCES Aktie. Handeln Sie für nur 5 Euro Orderprovision* pro Trade aus der Informationswelt von finanzen.net! BACK TO MAIN MENU Company Statements Gilead Announces Plans for New Location in North Carolina’s Research Triangle Region Dedicated to Business Services Gilead Sciences Statement on the Passing of the Honorable George P. Shultz, PhD Gilead Sciences Statement on Recent Events in Washington, D.C. Gilead Announces New Arm of HIV Women’s Prevention Study to Evaluate the … Cookie Notice ().
Gilead Sciences | 383,535 followers on LinkedIn. By using this site you agree to the
In December, Gilead Sciences submitted filgotinib to the FDA along with a priority review voucher, which reduces the review time. Verzögerung Deutsche Börse: 15 Min., Nasdaq, NYSE: 20 Min. FOSTER CITY (dpa-AFX) - Gilead Sciences Inc.'s. Why Is Gilead (GILD) Down 1.8% Since Last Earnings Report? Kursinformationen von SIX Financial Information. Übersicht über Kursziele der GILEAD SCIENCES Aktie, historische Kursziele … All quotes are in local exchange time. The Most Popular Guru Buys of the 4th Quarter, Intercept's (ICPT) Q4 Loss Wider than Expected, Sales Miss, FATE Reports Wider-Than-Expected Q4 Loss on Higher Expenses, The Zacks Analyst Blog Highlights: Apple, Procter & Gamble, Deere, T-Mobile US and Gilead Sciences, Top Analyst Reports for Apple, P&G, Deere & Others, Mizuho Securities Keeps Their Buy Rating on Gilead Sciences (GILD), 3 Biotech Stocks to Buy As Things Heat Up for the Sector, The Benefits of Moringa Could be Used in the Pandemic Fight, Gilead (GILD) & Galapagos Discontinue Development of IPF Drug. Handeln Sie für nur 5 Euro Orderprovision* pro Trade aus der Informationswelt von finanzen.net! Log in to see them here or sign up to get started. An Analyst Says It Should Test Its Cat Remdesivir Next. Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with … Zeit Aktuelle Aktienempfehlungen Potential (Euro) Potential Analyst; Aktuell sind keine Analysen verfügbar, die den gewählten Kriterien entsprechen. 16.06.2020 - Gilead Sciences, Inc. (Nasdaq: GILD) announced today that Javier Rodriguez has been appointed to the company’s Board of Directors. It’s simply what hasn’t been achieved yet. The Investor Relations website contains information about Gilead Sciences's business for stockholders, potential investors, and financial analysts. i kurtage. The company strives to … – Lenacapavir Maintained High Rates of Virologic Suppression Among Heavily Treatment-Experienced People with Multi-Drug Resistant HIV – – Late-Breaking Preclinical Data Support... | March 12, 2021 Gilead Sciences (US) Kurs 62,52 USD Land U.S.A. Børs NASDAQ. Gilead is a member of the NASDAQ Biotechnology Index and the S&P 500 Ziel des Unternehmens ist es, die weltweite Versorgung von Patienten, die an lebensbedrohlichen Krankheiten leiden, zu verbessern. Kurs fra 08.01.2021 You run a risk when you invest in financial instruments. Køb Gilead Sciences, Inc. (GILD) aktien. Gilead Sciences ist ein biopharmazeutisches Unternehmen, das innovative Arzneimittel in Bereichen erforscht, entwickelt und vermarktet, deren medizinischer Bedarf bisher nicht gedeckt wurde. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. GILEAD SCIENCES Fundamentalanalyse - hier erhalten Sie eine Analyse der GILEAD SCIENCES Aktie nach fundamentalen Kennzahlen wie KGV, … Intraday Data provided by FACTSET and subject to terms of use. This browser is no longer supported at MarketWatch. Create a list of the investments you want to track. Historical and current end-of-day data provided by FACTSET. GILEAD SCIENCES, INC. : Finanzkennzahlen und Gewinneschätzungen der Analysten, Bilanzsituation und Unternehmensbewertung GILEAD SCIENCES, INC. | 885823 | Subscriber Agreement & Terms of Use,
| 6-Punkte-Check (+Rangliste) Very scary. Gilead Sciences, Inc. / ˈ ɡ ɪ l i ə d /, is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV, hepatitis B, hepatitis C, and influenza, including Harvoni and Sovaldi. Hos Nordnet kan du handle fra 0 kr. Gilead Sciences, Inc. NASDAQ: GILD $63.58 down $0.33 (-0.52%) ICPT. Aktueller Aktienkurs Gilead Sciences Der aktuelle Kurs der Gilead Sciences Aktie beträgt 53.745 und hat sich heute um -0.9% verändert. 21.01.2020 - Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its fourth quarter and full year 2019 financial results will be released on Tuesday, February 4, after the market closes. Information and recommendations on these pages are general information and not personal advice. Visit a quote page and your recently viewed tickers will be displayed here. Oskar ist der einfache und intelligente ETF-Sparplan. Aktien » Nachrichten » GILEAD SCIENCES AKTIE » Gilead Sciences, Inc.: Kite's Tecartus (KTE-X19) Granted Conditional Marketing Authorization for the … The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster, CA. Gilead Sciences, Inc. is a research-based biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intercept Pharmaceuticals NASDAQ: ICPT $20.95 up $0.63 (3.10%) Related Articles.
Allopurinol 100 Mg Tabletten, Renault Grand Scénic 4, F1 Test Barcelona 2021, Magnus Resch Eltern, Click Heaters Reviews, Coldest Ice Packs For Injury, Typisch Amerikanische Produkte, Reinert Sommerwurst Angebot, Würzburg Outlet Rottendorf,
Allopurinol 100 Mg Tabletten, Renault Grand Scénic 4, F1 Test Barcelona 2021, Magnus Resch Eltern, Click Heaters Reviews, Coldest Ice Packs For Injury, Typisch Amerikanische Produkte, Reinert Sommerwurst Angebot, Würzburg Outlet Rottendorf,